Bond.az - H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stock and maintained its $56.00 price target. The target aligns with the analyst high target among Wall Street analysts.
The consensus recommendation stands at 1.2. The firm noted the company presented post hoc analysis from its pivotal Launch-HTN trial at the European Meeting on Hypertension and Cardiovascular Protection in Gdansk, Poland.
The analysis focused on lorundrostat, a novel aldosterone synthase inhibitor for uncontrolled or resistant hypertension. Data showed statistically significant blood pressure reductions in chronic kidney disease patients.
It also showed significantly reduced urine albumin-to-creatinine ratio and a consistent safety profile over 12 weeks. Key opinion leaders noted effective blood pressure reductions regardless of kidney disease status.
Mineralys has a PDUFA target date of December 22, 2026. For deeper insights, investors can access comprehensive reports. This article was generated with AI support and reviewed by an editor.
